Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Osteonecrosis of the jaw Stories

2012-02-08 07:00:00

THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC). Amgen will discuss results of the pivotal Phase 3 '147...

2012-01-27 10:32:21

Findings could lead to a screening test Researchers at the Columbia University College of Dental Medicine have identified a genetic variation that raises the risk of developing serious necrotic jaw bone lesions in patients who take bisphosphonates, a common class of osteoclastic inhibitors. The discovery paves the way for a genetic screening test to determine who can safely take these drugs. The study appears in the online version of the journal The Oncologist. Oral bisphosphonates are...

2011-12-29 16:32:00

THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases. The ODAC will review results from clinical...

2011-12-20 04:15:00

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is repeating the warning given by the AARP that coffee might block the absorption or increase the effects of some medications. New York, NY (PRWEB) December 19, 2011 According to a piece posted at the website of AARP on December 5, âœthe coffee you drink in the morning with some of your prescription drugs can either block their absorption or...

2011-12-07 11:26:43

Research: Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: Population based retrospective cohort study People who take bisphosphonates after joint replacement surgery are less likely to need a repeat operation, finds a new study published on bmj.com today. While hip and knee replacements are cost effective procedures, substantial numbers of patients require revision surgery within 10 years to replace the implant because of...

2011-12-02 00:22:00

EAST HANOVER, N.J., Dec. 2, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases. The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), held from December 6-10, will feature data presentations from...

2011-11-21 16:05:00

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, notes with some regret a report that a âœnovel treatment known as whole-body vibration doesnât appear to improve the bone health of postmenopausal women who are at high risk of developing osteoporosis.â New York, NY (PRWEB) November 21, 2011 According to a November 15 piece published by U.S. News and World Report, the treatment,...

2011-11-15 17:41:00

THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer (CRPC). Published in The Lancet, the study found XGEVA significantly prolonged bone metastasis-free survival, delayed time to bone metastasis and reduced the...

2011-11-05 16:10:00

THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal women with osteoporosis was associated with continued increase in bone mineral density (BMD) and consistent reduction in markers of bone turnover. These results will be presented on Nov. 8, 2011, at...

2011-09-26 07:00:00

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, has commissioned and published an infographic to educate the public about the history and dangers of the medication. New York, NY (PRWEB) September 26, 2011 The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, has commissioned and published an infographic to educate the public about the history and dangers of the...